Diagnosis of growth hormone deficiency after pituitary surgery: the combined acipimox/GH-releasing hormone test.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a controlled clinical trial.

Who Took Part

The abstract describes 35 patients taking part.

By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults and older adults, both men and women.

The researchers evaluated 35 patients [mean age 53.0 years; mean body mass index (BMI) 26.7 kg/m2] after pituitary surgery.

The researchers compared GH responses after acipimox and GHRH with the GH response during an insulin tolerance test (ITT) and, in a subgroup of 12 patients, with the GHRH/arginine test.

How the Study Was Run

The acipimox/GHRH test was additionally performed in 21 control subjects (mean age 53.8 years; mean BMI 24.7 kg/m2).

What Was Measured

The subject headings attached to it are Adenoma, Area Under Curve, Arginine, Fatty Acids, Nonesterified, Growth Hormone, Growth Hormone-Releasing Hormone and Insulin.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 35 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2003 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.